Immix Biopharma, Inc. financial data

Symbol
IMMX on Nasdaq
Location
Los Angeles, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 07 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 170% % -67%
Debt-to-equity 35% % 106%
Return On Equity -264% % -157%
Return On Assets -120% % -48%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33,577,873 shares 22%
Common Stock, Shares, Outstanding 33,035,515 shares 20%
Entity Public Float $32,432,613 USD 16%
Common Stock, Value, Issued $3,311 USD 20%
Weighted Average Number of Shares Outstanding, Basic 31,926,651 shares 8.5%
Weighted Average Number of Shares Outstanding, Diluted 31,926,651 shares 8.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $11,906,029 USD -8.5%
General and Administrative Expense $12,144,230 USD 21%
Operating Income (Loss) $24,050,259 USD -4.3%
Nonoperating Income (Expense) $524,665 USD -51%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $23,525,594 USD -6.9%
Income Tax Expense (Benefit) $37,243 USD -2.9%
Net Income (Loss) Attributable to Parent $23,562,837 USD -7.6%
Earnings Per Share, Basic 0 USD/shares 11%
Earnings Per Share, Diluted 0 USD/shares 11%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $15,947,308 USD -19%
Other Assets, Current $132,764 USD 264%
Assets, Current $16,584,280 USD -27%
Property, Plant and Equipment, Net $2,358,783 USD 74%
Operating Lease, Right-of-Use Asset $1,005,434 USD -0.47%
Other Assets, Noncurrent $20,418 USD 0%
Assets $20,080,604 USD -20%
Accounts Payable, Current $7,050,462 USD 114%
Employee-related Liabilities, Current $438,243 USD 121%
Liabilities, Current $10,850,581 USD 65%
Operating Lease, Liability, Noncurrent $965,053 USD -6%
Liabilities $11,815,634 USD 56%
Accumulated Other Comprehensive Income (Loss), Net of Tax $62,464 USD -67%
Retained Earnings (Accumulated Deficit) $93,775,454 USD -34%
Stockholders' Equity Attributable to Parent $13,251,203 USD -19%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $8,264,970 USD -53%
Liabilities and Equity $20,080,604 USD -20%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,685,140 USD 56%
Net Cash Provided by (Used in) Financing Activities $15,948,567 USD 13312%
Net Cash Provided by (Used in) Investing Activities $67,713 USD 78%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 33,107,878 shares 20%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,760,853 USD -115%
Deferred Tax Assets, Valuation Allowance $15,764,554 USD 107%
Operating Lease, Liability $1,106,335 USD 1.6%
Depreciation $38,153 USD 1168%
Payments to Acquire Property, Plant, and Equipment $67,713 USD -78%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $21,749,098 USD -41%
Lessee, Operating Lease, Liability, to be Paid $1,505,594 USD -4%
Property, Plant and Equipment, Gross $64,495 USD 0%
Operating Lease, Liability, Current $141,282 USD 125%
Lessee, Operating Lease, Liability, to be Paid, Year Two $158,325 USD 3.5%
Lessee, Operating Lease, Liability, to be Paid, Year One $218,971 USD 48%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $399,259 USD -17%
Lessee, Operating Lease, Liability, to be Paid, Year Three $163,866 USD 3.5%
Deferred Tax Assets, Operating Loss Carryforwards $6,708,668 USD 64%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $163,866 USD
Additional Paid in Capital $102,074,612 USD 16%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%